SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum
GLD 423.31-0.6%4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TobagoJack who wrote (151907)12/7/2019 9:43:06 AM
From: Pogeu Mahone1 Recommendation

Recommended By
marcher

  Read Replies (1) of 219366
 
That drug is a loser. If the developers cannot determine if it helps it does not!

Please do not give false hope to millions at ridiculous expense where a placebo wouldl work as well.

I believe Biogen has the muscle to get this approved.

If approved the FDA should be shot.

How could Biogen's data hold up?

After at least 5 years of research Biogen says this:

4 December 2019, 23:00 GMT+8
Biogen Inc. stunned Alzheimer’s researchers in March when it said its highly awaited Alzheimer’s treatment aducanumab was unlikely to work.

Than this 6 months later

Biogen Explains How Its Alzheimer’s Drug Went From Poor to Promising

BY ALICE PARK
DECEMBER 6, 2019

It doesn’t happen often—in fact, hardly ever—that a company decides to stop studying a promising drug it’s developing and then a few months later asks the Food and Drug Administration (FDA) to consider approving it.

But that’s exactly what occurred with aducanumab, an Alzheimer’s drug being developed by U.S. pharmaceutical company Biogen and its partner, Eisai, a Japanese pharma outfit. The surprising reversal has left patients, researchers and doctors with a lot of questions—especially since the drug is the first one to, if approved, treat the root causes of Alzheimer’s disease, which affects more than five million people in the U.S. This week, at the Clinical Trials on Alzheimer’s Disease conference in San Diego, Biogen tried to provide some answers in its first detailed public disclosure of the data on its aducanumab study, but the analysis is complex.

RELATED STORIES

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News